Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT. The overall incidence of reported adverse events was similar between treatment arms. D

Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC

BASEL, Switzerland--(BUSINESS WIRE)--Bayer Invests €100 million in Sustainable Health Products to Advance Company's 2030 Sustainability Commitments

Bayer Invests €100 million in Sustainable Health Products to Advance Company's 2030 Sustainability Commitments

Bristol-Myers

British American Tobacco

Imperial Brands PLC

Intel

Merck

Roche Holding AG

Sanofi

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The December 2021 Heat Map

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer presented new analyses of data from the comprehensive Phase III finerenone clinical trial program, which analyzed KERENDIA® (finerenone) – the first nonsteroidal mineralocorticoid receptor antagonist (MRA)2,3 – versus placebo and in addition to standard of care on cardiovascular (CV) outcomes, including hospitalization for heart failure (HF), across a spectrum of chronic kidney disease (CKD) severity in patients with type 2 diabetes (T2D).1,4 Data from the

Bayer Presented New Analyses Investigating KERENDIA® (finerenone) on Cardiovascular Outcomes in Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

German drugs and pesticides maker Bayer has no plans to split its three main businesses into separately traded companies, Chief Executive Werner Baumann said, amid a flurry of conglomerates moving to break themselves up.

Breaking up is not for us, Bayer CEO says

Microsoft

Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries tied to agriculture. The financial terms of the arrangement remain undisclosed.

Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities

MONHEIM, Germany--(BUSINESS WIRE)--Today, Bayer announced a strategic partnership with Microsoft to build a new cloud-based set of digital tools and data science solutions for use in agriculture and adjacent industries, bringing new infrastructure and foundational capabilities to accelerate innovation, boost efficiency and support sustainability across value chains. Agriculture and agribusinesses today benefit from a wide range of digital tools and data-powered insights through platforms like B

Bayer, Microsoft Enter Into Strategic Partnership to Optimize and Advance Digital Capabilities for Food, Feed, Fuel, Fiber Value Chain

Amazon

AstraZeneca

Alphabet

Recursion Pharmaceuticals

Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are too complex for humans to discern.

Artificial Intelligence In Drug Discovery

ST. LOUIS--(BUSINESS WIRE)--Harvest is a time for North American farmers to reflect on the past season's successes and challenges, while looking ahead to what's next. Bayer – with No. 1 market positions in corn, soybean and cotton acres in the U.S. – is also excited about the future and the next round of cutting-edge technologies for growers in 2022 and beyond. Among Bayer's milestones during the 2021 season: XtendFlex® Soybeans Launch: As Bayer's second major soybean trait launch in the last f

Bayer Focuses on Farmers and Drives Innovation into 2022

Investing in Bayer isn't for the faint-hearted given the company's recent and likely future valuation and earnings volatility. However, beneath the hood there's a qualitative company with superb fundamentals and an excellent portfolio.

Bayer - Cheap Again, Plenty Of Volatility, But Still A 'Buy'

Werner Enterprises

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2021 Results - Earnings Call Transcript

Bayer's (BAYRY) earnings in the third quarter of 2021 beat estimates. Revenues surge year over year.

Bayer's (BAYRY) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

German pharmaceutical-and-chemical conglomerate Bayer AG on Tuesday swung to a profit for the third quarter and said sales rose, driven by a recovery in its agriculture business.

Bayer swings to a profit as sales rise and adjusts outlook

LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Rodrigo Santos (48) to the company's Board of Management and the position of President of the Crop Science division, effective January 1, 2022. Santos will succeed Liam Condon (53), who has informed the Supervisory Board that, in order to pursue career opportunities outside of Bayer, he wishes to bring forward the end date of his contract with the company from December 31, 2023 to December 31, 2021. Santos is

Effective January 1, 2022: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science Division

Bayer said on Tuesday the head of its crop science unit, Liam Condon, would quit at the end of the year to pursue other career opportunities, following disappointing results earlier this year.

Bayer says head of agriculture unit quits

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Pharmaceuticals, working with The Life Raft Group (LRG), announced today that they have extended a research collaboration to broaden access to comprehensive genomic testing for Gastrointestinal Stromal Tumor (GIST) patients. This collaboration aims to advance precision medicine in oncology and use comprehensive genomic testing to identify patients in the United States (U.S.) who may benefit from personalized care. Comprehensive genomic testing, also known

Bayer Pharmaceuticals and The Life Raft Group, a Non-Profit, Announce Innovative Collaboration to Accelerate Cancer Research for GIST Patients

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced a new subgroup analysis of the prespecified pooled analysis, FIDELITY, which analyzed kidney and cardiovascular (CV) outcomes versus placebo by baseline sodium-glucose co-transporter-2 inhibitor (SGLT2i) use.1 These results add to the growing body of data on the renal and CV outcomes of KERENDIA® (finerenone), the first nonsteroidal mineralocorticoid receptor antagonist (MRA) for adult patients with chronic kidney disease (CKD) associated with ty

Bayer Presents New Subgroup Analysis of Prespecified Pooled Analysis of Phase III Studies for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without SGLT2i Use at Baseline

WHIPPANY, N.J.--(BUSINESS WIRE)--For the second consecutive year, the Bayer Consumer Health Media Team has been selected as the winner in the Best In-House Media Operations category during the 2021 AdExchanger Awards. The team also earned Best In Show for Overall Excellence in Programmatic Media. The AdExchanger Awards celebrate excellence in digital marketing and advertising. “Our in-house approach harnesses the power and passion of our employees as no one knows our business and brands better

Bayer Consumer Health Media Team Named AdExchanger Winner for Best In-House Media Operations

Agricultural seeds and chemicals supplier Bayer AG is expanding its carbon farming program to members of U.S. farm cooperative CHS Inc, boosting incentives for members to participate in the program, the companies said on Wednesday.

U.S. farm co-op CHS to pay members to enroll in Bayer carbon farming program

ST. LOUIS & INVER GROVE HEIGHTS, Minn.--(BUSINESS WIRE)--Bayer announced today with CHS Inc. a unique agreement that makes Bayer Crop Science the carbon program partner for CHS.

Bayer and CHS Collaborate to Bring Carbon Program Access to More Farmers

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new cardiovascular (CV) and renal subgroup analyses for KERENDIA® (finerenone) from the comprehensive clinical trial program, including the FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)'s Kidney Week 2021 from November 4-7, 2021. These data will be presented in scientific sessions in two oral presentations and two late-breaking posters, continuing to add to the gro

Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)

Bayer sees no impact on its full-year guidance from customers' changing planting habits or a five-week shutdown at its main glyphosate production site in Louisiana after Hurricane Ida, the German life science group said on Tuesday.

Bayer sees no guidance hit from hurricane, planting trends

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced continued progress in delivering customer-focused, sustainable agricultural innovation in an update with investors. The company's success in translating research and development (R&D) leadership into differentiated and advanced products for farmers is driving operational performance, while shaping the future of agriculture. Progress is being powered by strong commercial execution in a positive market environment, particularly in fungi

Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation

Bayer is evaluating its legal options after Mexican health regulators for the first time rejected a GMO corn permit it was seeking, the German pharmaceutical and crop science giant said in a statement to Reuters on Friday, blasting the decision as "non-scientific."

Bayer blasts 'unscientific' rejection by Mexican regulator of GMO corn permit

Shares in Bayer AG rose 2.5% in pre-market trade on Wednesday after the German agricultural and pharmaceuticals firm won its first trial over claims its Roundup weedkiller causes cancer.

News for Bayer AG Stock (BAYRY)